Zepsun (donafenib)

News alerts, weekly reports and conference planners

Company:

Suzhou Zelgen

Drug class:

Multi-tyrosine kinase inhibitor, cRAF inhibitor

Related drugs:

‹

›

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	ZG19018 + donafenib Sensitive: D – Preclinical ZG19018 + donafenib Sensitive : D	ZG19018 + donafenib Sensitive: D – Preclinical ZG19018 + donafenib Sensitive : D
TP53 wild-type	Hepatocellular Cancer	TP53 wild-type	Hepatocellular Cancer	donafenib Sensitive: D – Preclinical donafenib Sensitive : D	donafenib Sensitive: D – Preclinical donafenib Sensitive : D

Associations
(2)